Top Markets
Coin of the day
Cortexyme, Inc. Cortexyme, Inc.

Cortexyme, Inc.

CRTX
Rank in Stocks #25182
Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to... Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to pioneering new therapies for Alzheimer's and various other degenerative conditions. The company's primary investigational drug, atuzaginstat (also known as COR388), is an orally delivered, small molecule inhibitor engineered to cross the blood-brain barrier and target gingipain. This compound is currently in Phase II/III clinical trials, where it is being assessed for its potential use in individuals with mild to moderate Alzheimer's disease, as well as for tackling oral squamous cell carcinoma, periodontitis, and coronavirus infections. Established in 2012, Cortexyme, Inc. is headquartered in South San Francisco, California.
Share Price
$1.95
Last synced: 2022-07-29
Market Cap
$52.48M
Change (1 day)
2.63%
Change (1 year)
0.00%
Country
US
Trade Cortexyme, Inc. (CRTX)

Category

Number of shares outstanding for Cortexyme, Inc. (CRTX)
Number of shares outstanding as of August 2026: 0
According to Cortexyme, Inc. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Cortexyme, Inc. (CRTX) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
253.90M -
US
62.19M -
NL
483.58M -
AU
- -
CH
396.00M -
US